No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - Life sciences business Aptamer said on Monday that its current sales pipeline was "strong", with over £3.0m in advanced stage discussions.
Aptamer said a proportion of these advanced-stage deal negotiations were anticipated to progress through its laboratory before the end of the financial year, with the anticipated deal value being in addition to the roughly £1.4m of existing signed deals already at various stages of completion in the production laboratory.
The AIM-listed group noted that revenue recognition on all signed deals was further subject to the receipt of target material in a timely manner from customers and scientific attrition.
Aptamer added that it was continuing to make strides in rebuilding its sales pipeline and "revitalising operations" throughout the laboratory, leading to a growing pipeline conversion, including the successful acquisition of repeat business.
"The company looks forward to providing further updates on conversion of the pipeline to contracts before the year-end. Additionally, there is considerable potential for significant value delivery from ongoing activities in the drug delivery space, with a growing interest from various companies seeking to address the substantial unmet need in this field using Optimer and Optimer+ technologies," said Aptamer.
As of 1415 BST, Aptamer shares were up 2.33% at 0.75p.
Reporting by Iain Gilbert at Sharecast.com
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.
